Los Angeles, CA -- Nov 19, 2026 -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - will host an investor webinar at 5:00 PM Eastern Time to discuss results for the third quarter ended September 30, 2026, and provide an update on recent business developments.
Michael Heltzen, CEO of eXoZymes, states, “We're entering an exciting new phase for eXoZymes as we advance our lead product toward commercial manufacturing while expanding our pipeline of high-value molecules. Our progress with Curia and the advancement of additional product candidates demonstrate how we intend to turn our technology into a repeatable engine for commercial opportunities. We believe our ability to move rapidly from discovery toward scalable production is what sets our platform apart.”
Third quarter highlights
Investors and interested parties can access the live webinar through eXoZymes' investor relations website at:
https://video.exozymes.com/exoz-investor-update-3q26-nov-19
Michael Heltzen, CEO of eXoZymes, will lead the call and be joined by select members of the management team to review recent developments and ongoing initiatives. A recording and transcript of the conference call will also be made publicly available following the event.
About eXoZymes
Founded in 2019, eXoZymes is pioneering a cell-free biomanufacturing platform that uses AI-enhanced enzymes - called exozymes - to make valuable natural products and new analogs outside living cells. The company's platform is designed to replace inefficient extraction and petrochemical processes with a scalable way to produce high-value molecules for nutraceutical and pharmaceutical markets.
eXoZymes is building a portfolio of biosolutions across NCT - now Tyferyn for human use - cannabinoid analogs, santalene, and other high-value natural product molecules, with potential commercialization paths that include partnerships, licensing and joint ventures. Learn more at exozymes.com
eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely,” “potential,” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of eXoZymes’ quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.